Elevated plasma factor XI predicts cardiovascular events in patients with type 2 diabetes: a long-term observational study
Main finding · Composite of MI, stroke or CV deathResult — go to the resultHazard ratio 10.94 95% CI 4.46–26.87Authors' conclusion
To our knowledge, this study is the first to show that in T2DM patients, elevated FXI could predict major CV events, including mortality, which suggest that anti-FXI agents might be a potential novel antithrombotic option in this disease.
Study context
- Population
- Patients with T2D (aged 66 ± 8 years, 40.6% women, median T2D duration 5 [2–10] years)
- Participants
- 133 patients
- Exposure
- Elevated plasma Factor XI (FXI) vs normal FXI
- Elevated FXIn = 25
- Outcome
- Composite of myocardial infarction (MI), stroke or CV death; CV mortality alone
- Follow-up
- Median 72 months
Methodological detailslong-term observational
- Long-term observational
Main finding
Composite of:
Hazard ratio
10.94
95% CI 4.46–26.87
P < 0.001
Elevated FXIvs Normal FXI
HR 10.94 (95% CI 4.46–26.87); P < 0.001
As reported in the abstract
- Composite endpoint events overall
- n = 21, 15.8%
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| CV death · median follow-up 72 months | 7.11 (2.61–19.31) | P < 0.001 | |
| 0.050.21520Hazard ratio (log scale) |
- Cardiovascular (CV) death — CV deaths overall
- n = 16, 12%
CV death · median follow-up 72 months
- FXI remained an independent predictor on multivariable analysis
Correlates of elevated FXI
- Elevated FXI positively associated with LDL-C and thrombin activatable fibrinolysis inhibitor, but not HbA1c, inflammatory markers or thrombin generation
Original publication
Elevated plasma factor XI predicts cardiovascular events in patients with type 2 diabetes: a long-term observational study. Cardiovasc Diabetol. Published 17 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →